Who are Nalfurafine HCl 5.0 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Korsuva, Nalfurafine HCl 2.5 µg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nalfurafine-hcl-5-0-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Nalfurafine HCl 5.0 µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nalfurafine HCl 5.0 µg (Nalfurafine HCl 5.0 µg) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kappa opioid receptor agonist. Area: Dermatology / Nephrology.

phase 3 Kappa opioid receptor agonist Kappa opioid receptor (KOR) Dermatology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Nalfurafine HCl 5.0 µg (Nalfurafine HCl 5.0 µg) — Acologix, Inc.. Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nalfurafine HCl 5.0 µg TARGET	Nalfurafine HCl 5.0 µg	Acologix, Inc.	phase 3	Kappa opioid receptor agonist	Kappa opioid receptor (KOR)
Korsuva	DIFELIKEFALIN	Vifor Intl	marketed	Kappa Opioid Receptor Agonist	Kappa-type opioid receptor	2021-01-01
Nalfurafine HCl 2.5 µg	Nalfurafine HCl 2.5 µg	Acologix, Inc.	phase 3	Kappa opioid receptor agonist	Kappa opioid receptor (KOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kappa opioid receptor agonist class)

Acologix, Inc. · 2 drugs in this class
Korea Arlico Pharm. Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nalfurafine HCl 5.0 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/nalfurafine-hcl-5-0-g. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab